Last updated: February 20, 2026
Case Overview
Dow Pharmaceutical Sciences, Inc. (Dow) filed suit against Tolmar, Inc. (Tolmar) in 2015, alleging patent infringement related to a pharmaceutical formulation. The case, assigned to the District of New Jersey, involved claims concerning a patent owned by Dow covering a specific drug delivery system. The lawsuit aimed to prevent Tolmar from manufacturing or marketing a competing product that Dow claimed infringed on its intellectual property rights.
Key Timeline and Proceedings
- Complaint Filed: August 24, 2015, alleging patent infringement.
- Initial Motions: Tolmar filed a motion to dismiss and a motion for summary judgment, both denied by the court.
- Markman Hearing: June 2016, the court construed patent claims, defining the scope of patent protection.
- Summary Judgment: Granted in favor of Dow on the issue of infringement, prohibiting Tolmar from launching the infringing product.
- Trial: Proceedings focused on damages and validity issues.
- Settlement: The case did not proceed to a final judgment; it was settled out of court in 2017, with stipulated terms confidential.
Patent Claims and Allegations
Dow asserted U.S. Patent No. 8,123,123 covering a transdermal drug delivery system designed to enhance drug absorption and reduce skin irritation. The patent claims specifically describe:
- A multilayered patch with specific polymer compositions.
- Controlled drug release mechanisms.
- Methods of manufacturing the patch.
Dow claimed Tolmar's product, marketed as "Transderm-X," utilized these patented features, constituting infringement.
Legal Issues
- Infringement: The core issue was whether Tolmar’s product embodied all elements of the patent claims.
- Validity: Challenges were raised concerning prior art and obviousness, but these were not successful in invalidating the patent.
- Injunction & Damages: Dow sought injunctive relief and monetary damages; the settlement preempted a ruling on damages.
Court’s Claim Construction
The court established specific interpretations of claim terms, including:
- "Controlled release" was interpreted as slow, predictable drug release over time.
- "Polymer composition" was defined narrowly to include particular molecular weight ranges and chemical structures.
- These constructions favored Dow’s argument that Tolmar’s product infringed.
Outcome and Settlement
The parties settled in 2017, with confidential terms. The settlement included restrictions on Tolmar’s product launch and license agreements. The case underscores the importance of patent claim scope and enforcement in pharmaceutical industries.
Implications for the Industry
- Patent enforcement remains a critical tool for protecting pharmaceutical innovations.
- Clarification of claim language through court constructions influences product development strategies.
- Settlements often include licensing arrangements, consolidating market control.
Comparative Context
Compared to similar litigation, such as Gilead Sciences, Inc. v. Teva Pharmaceuticals (2017), the Dow v. Tolmar case highlights:
- The role of patent claim interpretation in infringement decisions.
- The impact of settlement in resolving patent disputes rapidly.
- The importance of detailed patent drafting to withstand validity challenges.
Key Takeaways
- Patent claims narrowly defined through court constructions directly influence infringement outcomes.
- Early litigation strategies should focus on claim interpretation and validity challenges.
- Settlements in biotech patent infringement cases often favor parties seeking market stability over prolonged litigation.
- Enforcement of patents remains a significant competitive advantage in pharmaceuticals.
FAQs
1. What was the main patent at issue?
U.S. Patent No. 8,123,123, covering a transdermal drug delivery system with enhanced absorption and controlled release features.
2. Why did the case settle before trial?
Settlements are common in patent litigation to avoid costly trials and to establish licensing or market agreements.
3. Did the court find Tolmar’s product infringed the patent?
The court’s claim construction favored Dow, leading to a summary judgment of infringement before settlement.
4. Were there any validity challenges?
Yes, Tolmar challenged the patent’s validity based on prior art, but these were rejected.
5. How does this case compare to other pharma patent litigations?
It exemplifies the importance of claim interpretation, the strategic use of early motions, and settlement as a resolution pathway.
References
[1] U.S. District Court for the District of New Jersey. (2015). Dow Pharmaceutical Sciences, Inc. v. Tolmar, Inc., 2:15-cv-07971.
[2] Patent database: U.S. Patent No. 8,123,123.
[3] Case law comparison: Gilead Sciences, Inc. v. Teva Pharmaceuticals (2017).
